PharmaCyte Biotech Inc (PMCB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH207662D
- Pages: 55
- October 2018
- Total Views:1141
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc, is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company offers technology is used for the treatment of advanced and inoperable pancreatic cancer and diabetes. It develops cell-in-a-box cellulose-based live cell encapsulation technology. PharmaCyte's treatment for pancreatic cancer consists of the combination of live cells encapsulated using Cell-in-a-Box technology together with low doses of the anticancer prodrug ifosfamide. It conducts research in the areas of live cell encapsulation technology, pancreatic cancer, diabetes, cannabinoids and cancer and breast cancer, among others. PharmaCyte is headquartered in Laguna Hills, California, the US.
PharmaCyte Biotech Inc (PMCB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
PharmaCyte Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 10
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Nuvilex Acquires Rights To Live-Cell Encapsulation Technology For Diabetes From SG Austria 12
Partnerships 13
PharmaCyte Biotech Partners with Translational Drug Development and Clinical Network Services 13
PharmaCyte Biotech Enters into Co-Development Agreement with University of Technology Sydney 14
Licensing Agreements 15
PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore for Cannabis Therapies 15
PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore 16
Nuvilex Enters into Licensing Agreement with University of Technology Sydney 17
Equity Offering 18
PharmaCyte Biotech to Raise up to USD25 Million in Public Offering of Shares 18
PharmaCyte Biotech Raises USD1 Million in Private Placement of shares 19
Nuvilex to Raise up to USD50 Million in Public Offering of Shares 20
Nuvilex Completes First Tranche Of Private Placement Of Shares For USD 2 Million 21
Nuvilex Competes Private Placement Of Securities For USD 1.5 Million 22
Acquisition 23
Nuvilex Acquires 14.5% Stake In SGAustria, Life Science Company 23
Nuvilex Acquires Bio Blue Bird For USD 1.5 Million 24
PharmaCyte Biotech Inc-Key Competitors 25
PharmaCyte Biotech Inc-Key Employees 26
PharmaCyte Biotech Inc-Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Corporate Communications 28
Oct 10, 2017: PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors 28
Jul 26, 2017: PharmaCyte Biotech Appoints Dr. Linda S. Sher as Chief Medical Officer 29
Jul 10, 2017: PharmaCyte Biotech Appoints Dr. Michael M. Abecassis to Board of Directors 31
May 02, 2017: PharmaCyte Biotech Appoints Thomas Yuen to Board of Directors 32
Apr 03, 2017: PharmaCyte Biotech Appoints Dr. Mark Rabe Director of Cannabis Program Development 33
Legal and Regulatory 34
Nov 16, 2017: British Columbia Securities Commission Revokes Cease Trade Order on PharmaCyte Biotech Securities 34
Government and Public Interest 36
Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 36
Product News 37
Dec 05, 2017: PharmaCyte Biotech Announces Production of Master Cell Bank 37
Oct 17, 2017: PharmaCyte Biotech Research Identifies Enzyme Activity for Cannabinoid-Based Therapy to Fight Cancer 38
04/18/2017: PharmaCyte Biotech Discusses Future of Cannabis Research Program, Competitors and More with Program's Director 39
04/10/2017: PharmaCyte Biotech's Cannabis Research Program Sees Significant Progress in University of Northern Colorado Presentations 41
Feb 13, 2017: PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity 43
01/24/2017: PharmaCyte Going Head to Head with Eli Lillys Pancreatic Cancer Drug in New Clinical Trial 45
Jan 10, 2018: PharmaCyte Announces Completion of Master Cell Bank 47
Product Approvals 48
Feb 13, 2017: PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity 48
Jan 30, 2017: PharmaCyte Biotech Retains Facet Life Sciences to Guide Pancreatic Cancer Therapy Development Lifecycle with FDA 50
Jan 04, 2017: PharmaCyte Biotech Announces Pre-IND Meeting Date with FDA 51
Clinical Trials 52
Feb 21, 2017: PharmaCyte Biotech Discusses Patient Enrollment and TD2s Role in Upcoming Clinical Trial 52
Other Significant Developments 54
Feb 06, 2018: PharmaCyte Announces Completion of Preparatory Work and Commencement of Testing by Eurofins of Cells from Its Master Cell Bank 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55
List Of Figure
List of Figures
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
PharmaCyte Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PharmaCyte Biotech Inc, Deals By Therapy Area, 2012 to YTD 2018 9
PharmaCyte Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 10
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Nuvilex Acquires Rights To Live-Cell Encapsulation Technology For Diabetes From SG Austria 12
PharmaCyte Biotech Partners with Translational Drug Development and Clinical Network Services 13
PharmaCyte Biotech Enters into Co-Development Agreement with University of Technology Sydney 14
PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore for Cannabis Therapies 15
PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore 16
Nuvilex Enters into Licensing Agreement with University of Technology Sydney 17
PharmaCyte Biotech to Raise up to USD25 Million in Public Offering of Shares 18
PharmaCyte Biotech Raises USD1 Million in Private Placement of shares 19
Nuvilex to Raise up to USD50 Million in Public Offering of Shares 20
Nuvilex Completes First Tranche Of Private Placement Of Shares For USD 2 Million 21
Nuvilex Competes Private Placement Of Securities For USD 1.5 Million 22
Nuvilex Acquires 14.5% Stake In SGAustria, Life Science Company 23
Nuvilex Acquires Bio Blue Bird For USD 1.5 Million 24
PharmaCyte Biotech Inc, Key Competitors 25
PharmaCyte Biotech Inc, Key Employees 26
PharmaCyte Biotech Inc, Subsidiaries 27
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
PharmaCyte Biotech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc, is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company offers technology is used for the treatment of advanced and inoperable pancreatic cancer and diabetes. It develops cell-in-a-box cellulose-based live cell encapsulation technology. PharmaCyte's treatment for pancreatic cancer consists of the combination of live cells encapsulated using Cell-in-a-Box technology together with low doses of the anticancer prodrug ifosfamide. It conducts research in the areas of live cell encapsulation technology, pancreatic cancer, diabetes, cannabinoids and cancer and breast cancer, among others. PharmaCyte is headquartered in Laguna Hills, California, the US.
PharmaCyte Biotech Inc (PMCB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
PharmaCyte Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 10
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Nuvilex Acquires Rights To Live-Cell Encapsulation Technology For Diabetes From SG Austria 12
Partnerships 13
PharmaCyte Biotech Partners with Translational Drug Development and Clinical Network Services 13
PharmaCyte Biotech Enters into Co-Development Agreement with University of Technology Sydney 14
Licensing Agreements 15
PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore for Cannabis Therapies 15
PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore 16
Nuvilex Enters into Licensing Agreement with University of Technology Sydney 17
Equity Offering 18
PharmaCyte Biotech to Raise up to USD25 Million in Public Offering of Shares 18
PharmaCyte Biotech Raises USD1 Million in Private Placement of shares 19
Nuvilex to Raise up to USD50 Million in Public Offering of Shares 20
Nuvilex Completes First Tranche Of Private Placement Of Shares For USD 2 Million 21
Nuvilex Competes Private Placement Of Securities For USD 1.5 Million 22
Acquisition 23
Nuvilex Acquires 14.5% Stake In SGAustria, Life Science Company 23
Nuvilex Acquires Bio Blue Bird For USD 1.5 Million 24
PharmaCyte Biotech Inc-Key Competitors 25
PharmaCyte Biotech Inc-Key Employees 26
PharmaCyte Biotech Inc-Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Corporate Communications 28
Oct 10, 2017: PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors 28
Jul 26, 2017: PharmaCyte Biotech Appoints Dr. Linda S. Sher as Chief Medical Officer 29
Jul 10, 2017: PharmaCyte Biotech Appoints Dr. Michael M. Abecassis to Board of Directors 31
May 02, 2017: PharmaCyte Biotech Appoints Thomas Yuen to Board of Directors 32
Apr 03, 2017: PharmaCyte Biotech Appoints Dr. Mark Rabe Director of Cannabis Program Development 33
Legal and Regulatory 34
Nov 16, 2017: British Columbia Securities Commission Revokes Cease Trade Order on PharmaCyte Biotech Securities 34
Government and Public Interest 36
Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 36
Product News 37
Dec 05, 2017: PharmaCyte Biotech Announces Production of Master Cell Bank 37
Oct 17, 2017: PharmaCyte Biotech Research Identifies Enzyme Activity for Cannabinoid-Based Therapy to Fight Cancer 38
04/18/2017: PharmaCyte Biotech Discusses Future of Cannabis Research Program, Competitors and More with Program's Director 39
04/10/2017: PharmaCyte Biotech's Cannabis Research Program Sees Significant Progress in University of Northern Colorado Presentations 41
Feb 13, 2017: PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity 43
01/24/2017: PharmaCyte Going Head to Head with Eli Lillys Pancreatic Cancer Drug in New Clinical Trial 45
Jan 10, 2018: PharmaCyte Announces Completion of Master Cell Bank 47
Product Approvals 48
Feb 13, 2017: PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity 48
Jan 30, 2017: PharmaCyte Biotech Retains Facet Life Sciences to Guide Pancreatic Cancer Therapy Development Lifecycle with FDA 50
Jan 04, 2017: PharmaCyte Biotech Announces Pre-IND Meeting Date with FDA 51
Clinical Trials 52
Feb 21, 2017: PharmaCyte Biotech Discusses Patient Enrollment and TD2s Role in Upcoming Clinical Trial 52
Other Significant Developments 54
Feb 06, 2018: PharmaCyte Announces Completion of Preparatory Work and Commencement of Testing by Eurofins of Cells from Its Master Cell Bank 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55
List Of Figure
List of Figures
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
PharmaCyte Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PharmaCyte Biotech Inc, Deals By Therapy Area, 2012 to YTD 2018 9
PharmaCyte Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 10
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Nuvilex Acquires Rights To Live-Cell Encapsulation Technology For Diabetes From SG Austria 12
PharmaCyte Biotech Partners with Translational Drug Development and Clinical Network Services 13
PharmaCyte Biotech Enters into Co-Development Agreement with University of Technology Sydney 14
PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore for Cannabis Therapies 15
PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore 16
Nuvilex Enters into Licensing Agreement with University of Technology Sydney 17
PharmaCyte Biotech to Raise up to USD25 Million in Public Offering of Shares 18
PharmaCyte Biotech Raises USD1 Million in Private Placement of shares 19
Nuvilex to Raise up to USD50 Million in Public Offering of Shares 20
Nuvilex Completes First Tranche Of Private Placement Of Shares For USD 2 Million 21
Nuvilex Competes Private Placement Of Securities For USD 1.5 Million 22
Nuvilex Acquires 14.5% Stake In SGAustria, Life Science Company 23
Nuvilex Acquires Bio Blue Bird For USD 1.5 Million 24
PharmaCyte Biotech Inc, Key Competitors 25
PharmaCyte Biotech Inc, Key Employees 26
PharmaCyte Biotech Inc, Subsidiaries 27
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
PharmaCyte Biotech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 140 | 
November 2020
Page 99 | July 2020
Page 75 | July 2020
Page 114 | May 2020
Page 217 | April 2020